JP2017512825A5 - - Google Patents

Download PDF

Info

Publication number
JP2017512825A5
JP2017512825A5 JP2016561611A JP2016561611A JP2017512825A5 JP 2017512825 A5 JP2017512825 A5 JP 2017512825A5 JP 2016561611 A JP2016561611 A JP 2016561611A JP 2016561611 A JP2016561611 A JP 2016561611A JP 2017512825 A5 JP2017512825 A5 JP 2017512825A5
Authority
JP
Japan
Prior art keywords
agent according
antibody
nme7
seq
nos
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016561611A
Other languages
English (en)
Japanese (ja)
Other versions
JP6401292B2 (ja
JP2017512825A (ja
Filing date
Publication date
Priority claimed from PCT/US2014/050773 external-priority patent/WO2015023694A2/en
Application filed filed Critical
Priority claimed from PCT/US2015/024764 external-priority patent/WO2015157322A2/en
Publication of JP2017512825A publication Critical patent/JP2017512825A/ja
Publication of JP2017512825A5 publication Critical patent/JP2017512825A5/ja
Application granted granted Critical
Publication of JP6401292B2 publication Critical patent/JP6401292B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016561611A 2014-04-07 2015-04-07 抗ｎｍｅ抗体 Active JP6401292B2 (ja)

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US201461976390P 2014-04-07 2014-04-07
US61/976,390 2014-04-07
PCT/US2014/050773 WO2015023694A2 (en) 2013-08-12 2014-08-12 Method for enhancing tumor growth
USPCT/US2014/050773 2014-08-12
USPCT/US2014/061821 2014-10-22
USPCT/US2014/061821 2014-10-22
US201562114526P 2015-02-10 2015-02-10
US62/114,526 2015-02-10
US201562127746P 2015-03-03 2015-03-03
US62/127,746 2015-03-03
PCT/US2015/024764 WO2015157322A2 (en) 2014-04-07 2015-04-07 Anti-nme antibody

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018165618A Division JP6646118B2 (ja) 2014-04-07 2018-09-05 抗ｎｍｅ抗体

Publications (3)

Publication Number Publication Date
JP2017512825A JP2017512825A (ja) 2017-05-25
JP2017512825A5 true JP2017512825A5 (https=) 2017-07-06
JP6401292B2 JP6401292B2 (ja) 2018-10-10

Family

ID=54288530

Family Applications (5)

Application Number Title Priority Date Filing Date
JP2016561611A Active JP6401292B2 (ja) 2014-04-07 2015-04-07 抗ｎｍｅ抗体
JP2018165618A Active JP6646118B2 (ja) 2014-04-07 2018-09-05 抗ｎｍｅ抗体
JP2020001446A Active JP7042854B2 (ja) 2014-04-07 2020-01-08 抗ｎｍｅ抗体
JP2022040438A Pending JP2022095648A (ja) 2014-04-07 2022-03-15 抗ｎｍｅ抗体
JP2024032381A Pending JP2024084747A (ja) 2014-04-07 2024-03-04 抗ｎｍｅ抗体

Family Applications After (4)

Application Number Title Priority Date Filing Date
JP2018165618A Active JP6646118B2 (ja) 2014-04-07 2018-09-05 抗ｎｍｅ抗体
JP2020001446A Active JP7042854B2 (ja) 2014-04-07 2020-01-08 抗ｎｍｅ抗体
JP2022040438A Pending JP2022095648A (ja) 2014-04-07 2022-03-15 抗ｎｍｅ抗体
JP2024032381A Pending JP2024084747A (ja) 2014-04-07 2024-03-04 抗ｎｍｅ抗体

Country Status (11)

Country Link
US (4) US20170204196A1 (https=)
EP (2) EP3129476B1 (https=)
JP (5) JP6401292B2 (https=)
KR (2) KR20210107166A (https=)
CN (1) CN106414726A (https=)
AU (1) AU2015243948B2 (https=)
CA (1) CA2945162A1 (https=)
IL (2) IL248220A0 (https=)
SG (2) SG10201808867PA (https=)
TW (1) TWI746420B (https=)
WO (1) WO2015157322A2 (https=)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106414726A (zh) 2014-04-07 2017-02-15 米纳瓦生物技术公司 抗nme抗体
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
JP2020500031A (ja) * 2016-10-11 2020-01-09 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊抗体及び開裂酵素の使用
EP3600451B1 (en) * 2017-03-29 2025-12-24 Minerva Biotechnologies Corporation Agents for differentiating stem cells and treating cancer
JP2022527144A (ja) 2019-01-11 2022-05-31 ミネルヴァ バイオテクノロジーズ コーポレーション 抗可変ｍｕｃ１＊抗体およびその使用
EP3920693A4 (en) * 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
CN116367857A (zh) 2020-06-08 2023-06-30 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
KR20230028796A (ko) * 2020-06-26 2023-03-02 미네르바 바이오테크놀로지 코포레이션 항-nme 항체 및 암 또는 암 전이의 치료 방법
KR20250009592A (ko) 2022-04-12 2025-01-17 미네르바 바이오테크놀로지 코포레이션 항-가변 muc1* 항체 및 그의 용도
US20240261406A1 (en) 2023-02-02 2024-08-08 Minerva Biotechnologies Corporation Chimeric antigen receptor compositions and methods for treating muc1* diseases
WO2025049494A1 (en) 2023-08-29 2025-03-06 Minerva Biotechnologies Corporation Bacterial nme7 orthologs and uses thereof

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5631271A (en) 1986-11-29 1997-05-20 Serfontein; Willem J. Methods and preparations for the treatment and prophylaxis of metabolic disturbances
US5874285A (en) * 1996-09-13 1999-02-23 Incyte Pharmaceuticals, Inc. Polynucleotide encoding a novel human nm23-like protein
US6818749B1 (en) 1998-10-31 2004-11-16 The United States Of America As Represented By The Department Of Health And Human Services Variants of humanized anti carcinoma monoclonal antibody cc49
CA2384713A1 (en) 1999-09-29 2001-04-05 Human Genome Sciences, Inc. Colon and colon cancer associated polynucleotides and polypeptides
AUPR011700A0 (en) 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
US20050163784A1 (en) 2002-06-17 2005-07-28 Valentijn Linda J. Novel cancer therapies
CA2491017A1 (en) * 2002-07-03 2004-01-15 Immunogen, Inc. Antibodies to non-shed muc1 and muc16, and uses thereof
WO2004050860A2 (en) * 2002-12-04 2004-06-17 Diadexus, Inc. Compositions, splice variants and methods relating to colon specific genes and proteins
CA2611728A1 (en) 2005-06-08 2006-12-14 Millennium Pharmaceuticals, Inc. Methods for the identification, assessment, and treatment of patients with cancer therapy
WO2007072221A2 (en) 2005-11-10 2007-06-28 Aurelium Biopharma Inc. Surface marker-directed cancer therapeutics
US20100254996A1 (en) 2007-06-18 2010-10-07 Medimmune, Llc Synergistic treatment of cells that express epha2 and erbb2
DK2334703T3 (en) 2008-09-17 2015-10-05 Innate Pharma Configurations and methods for detection of tlr3
US20170204191A1 (en) 2008-10-06 2017-07-20 Cynthia C. Bamdad Muc1* antibodies
US20110195089A1 (en) 2008-10-08 2011-08-11 The Adminstrators Of The Tulane Educational Fund Compositions, methods, and kits for enhancing the immunogenicity of pathogenic antigens
SG176801A1 (en) * 2009-06-11 2012-01-30 Minerva Biotechnologies Corp Methods for culturing stem and progenitor cells
PH12013501201A1 (en) * 2010-12-09 2013-07-29 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
EP2768945B1 (en) * 2011-10-17 2022-01-05 Minerva Biotechnologies Corporation Media for stem cell proliferation and induction
CA2864872C (en) 2012-02-24 2022-07-05 Alteogen Inc. Modified antibody in which motif comprising cysteine residue is bound
AU2013243948A1 (en) * 2012-04-02 2014-10-30 Moderna Therapeutics, Inc. Modified polynucleotides for the production of proteins associated with human disease
CN111849874A (zh) * 2012-07-24 2020-10-30 米纳瓦生物技术公司 Nme变体物种表达和抑制
CN104717980A (zh) * 2012-08-14 2015-06-17 米纳瓦生物技术公司 干细胞增强疗法
CA2886161A1 (en) 2012-09-29 2014-04-03 The Trustees Of The University Of Pennsylvania Veterinary composition and methods for non-surgical neutering and castration
US20160326263A1 (en) 2013-02-20 2016-11-10 Minerva Biotechnologies Corporation NME Inhibitors and Methods of Using NME Inhibitors
IL240695B2 (en) * 2013-02-20 2024-03-01 Minerva Biotechnologies Corp Nme inhibitors and methods of using nme inhibitors
CN106414726A (zh) 2014-04-07 2017-02-15 米纳瓦生物技术公司 抗nme抗体
CA2976089C (en) 2015-02-10 2026-01-13 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies
CN105384825B (zh) 2015-08-11 2018-06-01 南京传奇生物科技有限公司 一种基于单域抗体的双特异性嵌合抗原受体及其应用
WO2018010140A1 (zh) 2016-07-14 2018-01-18 中国科学院生物物理研究所 I型干扰素受体抗体及其用途
WO2018054240A1 (en) 2016-09-20 2018-03-29 Wuxi Biologics (Shanghai) Co. Ltd. Novel anti-pcsk9 antibodies
JP2020500031A (ja) 2016-10-11 2020-01-09 ミネルバ バイオテクノロジーズ コーポレーション ヒト化抗ｍｕｃ１＊抗体及び開裂酵素の使用
WO2019104306A1 (en) 2017-11-27 2019-05-31 Minerva Biotechnologies Corporation Humanized anti-muc1* antibodies and direct use of cleavage enzyme
EP3920693A4 (en) 2019-02-04 2022-10-05 Minerva Biotechnologies Corporation ANTI-NME ANTIBODIES AND METHODS OF TREATMENT OF CANCER OR CANCER METASTASIS
CN116367857A (zh) 2020-06-08 2023-06-30 米纳瓦生物技术公司 抗nme抗体及治疗癌症或癌症转移的方法
KR20230028796A (ko) 2020-06-26 2023-03-02 미네르바 바이오테크놀로지 코포레이션 항-nme 항체 및 암 또는 암 전이의 치료 방법

Similar Documents

Publication Publication Date Title
JP2017512825A5 (https=)
JP2017504577A5 (https=)
JP2019535763A5 (https=)
JP2016525551A5 (https=)
MX2024013960A (es) Anticuerpos anti-ox40 y metodos de uso
JP2020536109A5 (https=)
PH12014500089A1 (en) Antibodies that bind to ox40 and their uses
JP2020524661A5 (https=)
MX2009010120A (es) Proteinas de union, incluyendo anticuerpos, derivados de anticuerpo y fragmentos de anticuerpo, que se unen especificamente cd154 y sus usos.
JP2017522903A5 (https=)
WO2017060322A3 (en) Ptefb-inhibitor-adc
JP2017176174A5 (https=)
JP2016527314A5 (https=)
JP2017500018A5 (https=)
MX2019012869A (es) Anticuerpos anti-sortilina y metodos para su uso.
JP2019506869A5 (https=)
NZ597023A (en) Monoclonal antibodies that bind to hGM-CSF and medical compositions comprising same
JP2016512214A5 (https=)
JP2020507561A5 (https=)
ES2776179T3 (es) Anticuerpos dirigidos contra determinantes de la superficie de S. aureus
RU2015136078A (ru) Антитело против с5 и способ предупреждения и лечения обусловленных комплементом заболеваний
RU2017105596A (ru) Антитела к церамиду
JP2021512159A5 (https=)
JP2019535306A5 (https=)
EA202190235A1 (ru) Антитела к cd33 и способы их применения